DERM Stock Risk & Deep Value Analysis

Journey Medical Corp

Healthcare • Drug Manufacturers - Specialty & Generic

DVR Score

8.0

out of 10

Hidden Gem

The Bottom Line on DERM

We analyzed Journey Medical Corp using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran DERM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 16, 2026•Run Fresh Analysis →

📈DERM Performance Overview3yr weekly

📊

Unlock DERM Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

DERM Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

Medium

Market Risk

Medium

About Journey Medical Corp (DERM)

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Market Cap Category

small

Market Cap

$195.61M

DERM Deep Value Analysis

Journey Medical (DERM) remains a high-risk, high-reward proposition largely predicated on the regulatory success of DFD-29 for rosacea. The NDA submission in late 2025 was a significant milestone, and the market is now anticipating the PDUFA decision, likely in Q3 2026. The rosacea market opportunity is substantial, and DFD-29 offers a differentiated profile. While the capital raise in 2025 extended their financial runway, the company's valuation is highly dependent on DFD-29's approval and successful commercialization. Leadership has demonstrated execution, but competitive and regulatory risks are paramount. A successful approval and launch could still be transformative, justifying strong growth potential.

DERM Red Flags & Warning Signs

⚠
DFD-29 Complete Response Letter (CRL) from FDA
⚠
Slower-than-expected DFD-29 commercial uptake post-approval
⚠
New competitive therapies entering the rosacea market

Unlock DERM Red Flags & Risk Warnings

Create a free account to see the full analysis

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

DERM Financial Health Metrics

Market Cap

$195.61M

DERM Competitive Moat Analysis

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

1 Identified

Intangible Assets/IP

The moat is primarily derived from patent protection for DFD-29, which provides a period of market exclusivity, estimated for 10-15 years post-approval. This allows time to build market share and brand recognition.

DERM Competitive Moat Analysis

DERM Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q1 2026 Earnings Report (estimated May 2026)
•DFD-29 PDUFA date (estimated Q3 2026, e.g., August 2026)

Medium-Term (6-18 months)

•DFD-29 Commercial Launch (expected late 2026 / early 2027)
•Initial DFD-29 sales figures and market penetration updates

Long-Term (18+ months)

•Significant market share capture in the rosacea treatment segment
•Potential label expansion for DFD-29 or pipeline development

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

🔔

Never miss a move on DERM

Create a free account to set price alerts and get notified on Telegram when DERM hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Journey Medical Corp (DERM)?

As of March 16, 2026, Journey Medical Corp has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Journey Medical Corp?

Journey Medical Corp's market capitalization is approximately $195.6M. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.

What ticker symbol does Journey Medical Corp use?

DERM is the ticker symbol for Journey Medical Corp. The company trades on the NCM.

What is the risk level for DERM stock?

Our analysis rates Journey Medical Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the DERM DVR analysis updated?

Our AI-powered analysis of Journey Medical Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 16, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.